Wednesday, February 01, 2023
Arima Genomics announced an agreement with Protean BioDiagnostics to make an Arima next-generation sequencing-based test available to clinicians for patient management through Protean BioDiagnostic’s CLIA-certified, CAP-accredited laboratory in Orlando, Florida.
Arima Genomics partnership with Protean brings Arima’s technology, to identify gene fusions and other rearrangements missed by existing methods, to the clinic.
The new testing service, makes use of Arima’s novel genomic technology, to identify clinically actionable gene fusions in tumour tissue from patients with cancer, and is expected to be available for order in the first half of 2023.
This partnership represents a significant change and helps how doctors can use Arima's technology to understand the molecules of cancer.
